Ophthalmic Drugs Market

Table of Content

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Market

4. Market Overview

    4.1. Introduction

        4.1.1. Disease Indication Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Key Market Indicators

    4.4. Market Dynamics

        4.4.1. Drivers

        4.4.2. Restraints

        4.4.3. Opportunity

        4.4.4. Trends

    4.5. Global Market Analysis and Forecasts, 2023–2033

        4.5.1. Market Revenue Projections (US$ Mn)

    4.6. Porter’s Five Force Analysis

    4.7. Market Outlook

    4.8. Global Company Share Analysis: Glaucoma; 2018

    4.9. Pipeline Analysis: Major Market Players

    4.10. Pipeline Analysis: Emerging Market Players

    4.11. Comparison matrix for product offerings: Major Market Players

    4.12. Snapshot: Causes of blindness - Global

    4.13. Snapshot: Causes of blindness - Regional

5. Global Market Analysis and Forecasts, By Disease Indication

    5.1. Introduction & Definition

    5.2. Key Findings / Developments

    5.3. Key Trends

    5.4. Market Value Forecast by Disease Indication, 2023–2033

        5.4.1. Dry Eye

        5.4.2. Glaucoma

        5.4.3. Infection/Inflammation

        5.4.4. Retinal Disorders

            5.4.4.1. Wet AMD

            5.4.4.2. Dry AMD

            5.4.4.3. Diabetic Retinopathy

            5.4.4.4. Others

        5.4.5. Allergy

        5.4.6. Uveitis

        5.4.7. Others

    5.5. Market Attractiveness by Disease Indication

6. Global Market Analysis and Forecasts, By Therapeutic Class

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Key Trends

    6.4. Market Value Forecast By Therapeutic Class, 2023–2033

        6.4.1. Anti-inflammatory Drugs

            6.4.1.1. NSAID

            6.4.1.2. Steroids

        6.4.2. Anti-infective Drugs

            6.4.2.1. Anti-fungal Drugs

            6.4.2.2. Anti-bacterial Drugs

            6.4.2.3. Others

        6.4.3. Anti-glaucoma Drugs

            6.4.3.1. Alpha Agonist

            6.4.3.2. Beta Blockers

            6.4.3.3. Prostaglandin Analogs

            6.4.3.4. Combined Medication

            6.4.3.5. Others

        6.4.4. Anti-allergy Drugs

        6.4.5. Anti-VEGF Agents

        6.4.6. Others

    6.5. Market Attractiveness by Therapeutic Class

7. Global Market Analysis and Forecasts, By Product Type

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Key Trends

    7.4. Market Value Forecast by Product Type, 2023–2033

        7.4.1. Prescription Drugs

        7.4.2. OTC Drugs

    7.5. Market Attractiveness by Product Type

8. Global Market Analysis and Forecasts, By Distribution Channels

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Key Trends

    8.4. Market Value Forecast by Distribution Channels, 2023–2033

        8.4.1. Hospital Pharmacies

        8.4.2. Online Pharmacies

        8.4.3. Independent Pharmacies & Drug Stores

    8.5. Market Attractiveness by Distribution Channels

9. Global Market Analysis and Forecasts, By Region

    9.1. Key Findings

    9.2. Policies and Regulations

    9.3. Market Value Forecast by Region

        9.3.1. North America

        9.3.2. Europe

        9.3.3. Asia Pacific

        9.3.4. Latin America

        9.3.5. Middle East and Africa

    9.4. Market Attractiveness by Country/Region

10. North America Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

        10.1.2. Policies and Regulations

        10.1.3. Key Trends

    10.2. Market Value Forecast by Disease Indication, 2023–2033

        10.2.1. Dry Eye

        10.2.2. Glaucoma

        10.2.3. Infection/Inflammation

        10.2.4. Retinal Disorders

            10.2.4.1. Wet AMD

            10.2.4.2. Dry AMD

            10.2.4.3. Diabetic Retinopathy

            10.2.4.4. Others

        10.2.5. Allergy

        10.2.6. Uveitis

        10.2.7. Others

    10.3. Market Value Forecast by Therapeutic Class, 2023–2033

        10.3.1. Anti-inflammatory Drugs

            10.3.1.1. NSAID

            10.3.1.2. Steroids

        10.3.2. Anti-infective Drugs

            10.3.2.1. Anti-fungal Drugs

            10.3.2.2. Anti-bacterial Drugs

            10.3.2.3. Others

        10.3.3. Anti-glaucoma Drugs

            10.3.3.1. Alpha Agonist

            10.3.3.2. Beta Blockers

            10.3.3.3. Prostaglandin Analogs

            10.3.3.4. Combined Medication

            10.3.3.5. Others

        10.3.4. Anti-allergy Drugs

        10.3.5. Anti-VEGF Agents

        10.3.6. Others

    10.4. Market Value Forecast by Product Type, 2023–2033

        10.4.1. Prescription Drugs

        10.4.2. OTC Drugs

    10.5. Market Value Forecast by Distribution Channels, 2023–2033

        10.5.1. Hospital Pharmacies

        10.5.2. Online Pharmacies

        10.5.3. Independent Pharmacies & Drug Stores

    10.6. Market Value Forecast by Country, 2023–2033

        10.6.1. U.S.

        10.6.2. Canada

    10.7. Market Attractiveness Analysis

        10.7.1. By Disease Indication

        10.7.2. By Therapeutic Class

        10.7.3. By Product Type

        10.7.4. By Distribution Channels

        10.7.5. By Country

11. Europe Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

        11.1.2. Policies and Regulations

        11.1.3. Key Trends

    11.2. Market Value Forecast by Disease Indication, 2023–2033

        11.2.1. Dry Eye

        11.2.2. Glaucoma

        11.2.3. Infection/Inflammation

        11.2.4. Retinal Disorders

            11.2.4.1. Wet AMD

            11.2.4.2. Dry AMD

            11.2.4.3. Diabetic Retinopathy

            11.2.4.4. Others

        11.2.5. Allergy

        11.2.6. Uveitis

        11.2.7. Others

    11.3. Market Value Forecast by Therapeutic Class, 2023–2033

        11.3.1. Anti-inflammatory Drugs

            11.3.1.1. NSAID

            11.3.1.2. Steroids

        11.3.2. Anti-infective Drugs

            11.3.2.1. Anti-fungal Drugs

            11.3.2.2. Anti-bacterial Drugs

            11.3.2.3. Others

        11.3.3. Anti-glaucoma Drugs

            11.3.3.1. Alpha Agonist

            11.3.3.2. Beta Blockers

            11.3.3.3. Prostaglandin Analogs

            11.3.3.4. Combined Medication

            11.3.3.5. Others

        11.3.4. Anti-allergy Drugs

        11.3.5. Anti-VEGF Agents

        11.3.6. Others

    11.4. Market Value Forecast by Product Type, 2023–2033

        11.4.1. Prescription Drugs

        11.4.2. OTC Drugs

    11.5. Market Value Forecast by Distribution Channels, 2023–2033

        11.5.1. Hospital Pharmacies

        11.5.2. Online Pharmacies

        11.5.3. Independent Pharmacies & Drug Stores

    11.6. Market Value Forecast by Country, 2023–2033

        11.6.1. U.K.

        11.6.2. Germany

        11.6.3. France

        11.6.4. Italy

        11.6.5. Spain

        11.6.6. Russia

        11.6.7. Rest of Europe

    11.7. Market Attractiveness Analysis

        11.7.1. By Disease Indication

        11.7.2. By Therapeutic Class

        11.7.3. By Product Type

        11.7.4. By Distribution Channels

        11.7.5. By Country

12. Asia Pacific Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

        12.1.2. Policies and Regulations

        12.1.3. Key Trends

    12.2. Market Value Forecast by Disease Indication, 2023–2033

        12.2.1. Dry Eye

        12.2.2. Glaucoma

        12.2.3. Infection/Inflammation

        12.2.4. Retinal Disorders

            12.2.4.1. Wet AMD

            12.2.4.2. Dry AMD

            12.2.4.3. Diabetic Retinopathy

            12.2.4.4. Others

        12.2.5. Allergy

        12.2.6. Uveitis

        12.2.7. Others

    12.3. Market Value Forecast by Therapeutic Class, 2023–2033

        12.3.1. Anti-inflammatory Drugs

            12.3.1.1. NSAID

            12.3.1.2. Steroids

        12.3.2. Anti-infective Drugs

            12.3.2.1. Anti-fungal Drugs

            12.3.2.2. Anti-bacterial Drugs

            12.3.2.3. Others

        12.3.3. Anti-glaucoma Drugs

            12.3.3.1. Alpha Agonist

            12.3.3.2. Beta Blockers

            12.3.3.3. Prostaglandin Analogs

            12.3.3.4. Combined Medication

            12.3.3.5. Others

        12.3.4. Anti-allergy Drugs

        12.3.5. Anti-VEGF Agents

        12.3.6. Others

    12.4. Market Value Forecast by Product Type, 2023–2033

        12.4.1. Prescription Drugs

        12.4.2. OTC Drugs

    12.5. Market Value Forecast by Distribution Channels, 2023–2033

        12.5.1. Hospital Pharmacies

        12.5.2. Online Pharmacies

        12.5.3. Independent Pharmacies & Drug Stores

    12.6. Market Value Forecast by Country, 2023–2033

        12.6.1. India

        12.6.2. China

        12.6.3. Japan

        12.6.4. Australia & New Zealand

        12.6.5. Rest of Asia Pacific

    12.7. Market Attractiveness Analysis

        12.7.1. By Disease Indication

        12.7.2. By Therapeutic Class

        12.7.3. By Product Type

        12.7.4. By Distribution Channels

        12.7.5. By Country

13. Latin America Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

        13.1.2. Policies and Regulations

        13.1.3. Key Trends

    13.2. Market Value Forecast by Disease Indication, 2023–2033

        13.2.1. Dry Eye

        13.2.2. Glaucoma

        13.2.3. Infection/Inflammation

        13.2.4. Retinal Disorders

            13.2.4.1. Wet AMD

            13.2.4.2. Dry AMD

            13.2.4.3. Diabetic Retinopathy

            13.2.4.4. Others

        13.2.5. Allergy

        13.2.6. Uveitis

        13.2.7. Others

    13.3. Market Value Forecast by Therapeutic Class, 2023–2033

        13.3.1. Anti-inflammatory Drugs

            13.3.1.1. NSAID

            13.3.1.2. Steroids

        13.3.2. Anti-infective Drugs

            13.3.2.1. Anti-fungal Drugs

            13.3.2.2. Anti-bacterial Drugs

            13.3.2.3. Others

        13.3.3. Anti-glaucoma Drugs

            13.3.3.1. Alpha Agonist

            13.3.3.2. Beta Blockers

            13.3.3.3. Prostaglandin Analogs

            13.3.3.4. Combined Medication

            13.3.3.5. Others

        13.3.4. Anti-allergy Drugs

        13.3.5. Anti-VEGF Agents

        13.3.6. Others

    13.4. Market Value Forecast by Product Type, 2023–2033

        13.4.1. Prescription Drugs

        13.4.2. OTC Drugs

    13.5. Market Value Forecast by Distribution Channels, 2023–2033

        13.5.1. Hospital Pharmacies

        13.5.2. Online Pharmacies

        13.5.3. Independent Pharmacies & Drug Stores

    13.6. Market Value Forecast by Country, 2023–2033

        13.6.1. Brazil

        13.6.2. Mexico

        13.6.3. Rest of Latin America

    13.7. Market Attractiveness Analysis

        13.7.1. By Disease Indication

        13.7.2. By Therapeutic Class

        13.7.3. By Product Type

        13.7.4. By Distribution Channels

        13.7.5. By Country

14. Middle East and Africa Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

        14.1.2. Policies and Regulations

        14.1.3. Key Trends

    14.2. Market Value Forecast by Disease Indication, 2023–2033

        14.2.1. Dry Eye

        14.2.2. Glaucoma

        14.2.3. Infection/Inflammation

        14.2.4. Retinal Disorders

            14.2.4.1. Wet AMD

            14.2.4.2. Dry AMD

            14.2.4.3. Diabetic Retinopathy

            14.2.4.4. Others

        14.2.5. Allergy

        14.2.6. Uveitis

        14.2.7. Others

    14.3. Market Value Forecast by Therapeutic Class, 2023–2033

        14.3.1. Anti-inflammatory Drugs

            14.3.1.1. NSAID

            14.3.1.2. Steroids

        14.3.2. Anti-infective Drugs

            14.3.2.1. Anti-fungal Drugs

            14.3.2.2. Anti-bacterial Drugs

            14.3.2.3. Others

        14.3.3. Anti-glaucoma Drugs

            14.3.3.1. Alpha Agonist

            14.3.3.2. Beta Blockers

            14.3.3.3. Prostaglandin Analogs

            14.3.3.4. Combined Medication

            14.3.3.5. Others

        14.3.4. Anti-allergy Drugs

        14.3.5. Anti-VEGF Agents

        14.3.6. Others

    14.4. Market Value Forecast by Product Type, 2023–2033

        14.4.1. Prescription Drugs

        14.4.2. OTC Drugs

    14.5. Market Value Forecast by Distribution Channels, 2023–2033

        14.5.1. Hospital Pharmacies

        14.5.2. Online Pharmacies

        14.5.3. Independent Pharmacies & Drug Stores

    14.6. Market Value Forecast by Country, 2023–2033

        14.6.1. South Africa

        14.6.2. GCC Countries

        14.6.3. Rest of Middle East and Africa

    14.7. Market Attractiveness Analysis

        14.7.1. By Disease Indication

        14.7.2. By Therapeutic Class

        14.7.3. By Product Type

        14.7.4. By Distribution Channels

        14.7.5. By Country

15. Competition Landscape

    15.1. Market Player – Competition Matrix (By Tier and Size of companies)

    15.2. Market Share Analysis by Company (2018)

    15.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)

        15.3.1. Aerie Pharmaceuticals, Inc.

            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strengths)

            15.3.1.2. Financial Overview

            15.3.1.3. Product Portfolio

            15.3.1.4. SWOT Analysis

            15.3.1.5. Strategic Overview

        15.3.2. ALLERGAN

            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strengths)

            15.3.2.2. Financial Overview

            15.3.2.3. Product Portfolio

            15.3.2.4. SWOT Analysis

            15.3.2.5. Strategic Overview

        15.3.3. Valeant Pharmaceuticals International, Inc.

            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strengths)

            15.3.3.2. Financial Overview

            15.3.3.3. Product Portfolio

            15.3.3.4. SWOT Analysis

            15.3.3.5. Strategic Overview

        15.3.4. Bayer AG

            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strengths)

            15.3.4.2. Financial Overview

            15.3.4.3. Product Portfolio

            15.3.4.4. SWOT Analysis

            15.3.4.5. Strategic Overview

        15.3.5. Genentech, Inc. (F. Hoffmann-La Roche Ltd.)

            15.3.5.1. Company Overview (HQ, Business Segments, Employee Strengths)

            15.3.5.2. Financial Overview

            15.3.5.3. Product Portfolio

            15.3.5.4. SWOT Analysis

            15.3.5.5. Strategic Overview

        15.3.6. Novartis AG

            15.3.6.1. Company Overview (HQ, Business Segments, Employee Strengths)

            15.3.6.2. Financial Overview

            15.3.6.3. Product Portfolio

            15.3.6.4. SWOT Analysis

            15.3.6.5. Strategic Overview

        15.3.7. Pfizer Inc.

            15.3.7.1. Company Overview (HQ, Business Segments, Employee Strengths)

            15.3.7.2. Financial Overview

            15.3.7.3. Product Portfolio

            15.3.7.4. SWOT Analysis

            15.3.7.5. Strategic Overview

        15.3.8. Regeneron Pharmaceuticals, Inc.

            15.3.8.1. Company Overview (HQ, Business Segments, Employee Strengths)

            15.3.8.2. Financial Overview

            15.3.8.3. Product Portfolio

            15.3.8.4. SWOT Analysis

            15.3.8.5. Strategic Overview

        15.3.9. Santen Pharmaceutical Co., Ltd.

            15.3.9.1. Company Overview (HQ, Business Segments, Employee Strengths)

            15.3.9.2. Financial Overview

            15.3.9.3. Product Portfolio

            15.3.9.4. SWOT Analysis

            15.3.9.5. Strategic Overview

        15.3.10. Shire

            15.3.10.1. Company Overview (HQ, Business Segments, Employee Strengths)

            15.3.10.2. Financial Overview

            15.3.10.3. Product Portfolio

            15.3.10.4. SWOT Analysis

            15.3.10.5. Strategic Overview

            15.3.10.6. Others

List Of Table

Table 01: Product Offering - Major Market Players

Table 02: Global Market Size (US$ Mn) Forecast, by Disease Indication, 2023–2033

Table 03: Global Market Size (US$ Mn) Forecast, Market Forecast, by Disease Indication – Retinal Disorder, 2023–2033

Table 04: Global Market Size (US$ Mn) Forecast, by Therapeutic Class, 2023–2033

Table 05: Global Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-inflammatory Drugs, 2023–2033

Table 06: Global Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-infective Drugs, 2023–2033

Table 07: Global Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-glaucoma Drugs, 2023–2033

Table 08: Global Market Size (US$ Mn) Forecast, by Product Type, 2023–2033

Table 09: Global Market Size (US$ Mn) Forecast, by Distribution Channel, 2023–2033

Table 10: Global Market Size (US$ Mn) Forecast, by Region, 2023–2033

Table 11: North America Market Size (US$ Mn) Forecast, by Country, 2023–2033

Table 12: North America Market Size (US$ Mn) Forecast, by Disease Indication, 2023–2033

Table 13: North America Market Size (US$ Mn) Forecast, Market Forecast, by Disease Indication – Retinal Disorder, 2023–2033

Table 14: North America Market Size (US$ Mn) Forecast, by Therapeutic Class, 2023–2033

Table 15: North America Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-inflammatory Drugs, 2023–2033

Table 16: North America Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-infective Drugs, 2023–2033

Table 17: North America Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-glaucoma Drugs, 2023–2033

Table 18: North America Market Size (US$ Mn) Forecast, by Product Type, 2023–2033

Table 19: North America Market Size (US$ Mn) Forecast, by Distribution Channels, 2023–2033

Table 20: Europe Market Size (US$ Mn) Forecast, by Country/Sub-Region, 2023–2033

Table 21: Europe Market Size (US$ Mn) Forecast, by Disease Indication, 2023–2033

Table 22: Europe Market Size (US$ Mn) Forecast, Market Forecast, by Disease Indication – Retinal Disorder, 2023–2033

Table 23: Europe Market Size (US$ Mn) Forecast, by Therapeutic Class, 2023–2033

Table 24: Europe Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-inflammatory Drug, 2023–2033

Table 25: Europe Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-infective Drug, 2023–2033

Table 26: Europe Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-glaucoma Drug, 2023–2033

Table 27: Europe Market Size (US$ Mn) Forecast, by Product Type, 2023–2033

Table 28: Europe Market Size (US$ Mn) Forecast, by Distribution Channel, 2023–2033

Table 29: Asia Pacific Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2033

Table 30: Asia Pacific Market Size (US$ Mn) Forecast, by Disease Indication, 2023–2033

Table 31: Asia Pacific Market Size (US$ Mn) Forecast, by Disease Indication – Retinal Disorder, 2023–2033

Table 32: Asia Pacific Market Size (US$ Mn) Forecast, by Therapeutic Class, 2023–2033

Table 33: Asia Pacific Market Size (US$ Mn) Forecast, by Therapeutic Class – Anti-inflammatory Drugs, 2023–2033

Table 34: Asia Pacific Market Size (US$ Mn) Forecast, by Therapeutic Class – Anti-infective Drugs, 2023–2033

Table 35: Asia Pacific Market Size (US$ Mn) Forecast, by Therapeutic Class – Anti-glaucoma Drugs, 2023–2033

Table 36: Asia Pacific Market Size (US$ Mn) Forecast, by Product Type, 2023–2033

Table 37: Asia Pacific Market Size (US$ Mn) Forecast, by Distribution Channel, 2023–2033

Table 38: Latin America Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2033

Table 39: Latin America Market Size (US$ Mn) Forecast, by Disease Indication, 2023–2033

Table 40: Latin America Market Size (US$ Mn) Forecast, by Disease Indication – Retinal Disorder, 2023–2033

Table 41: Latin America Market Size (US$ Mn) Forecast, by Therapeutic Class, 2023–2033

Table 42: Latin America Market Size (US$ Mn) Forecast, by Therapeutic Class – Anti-inflammatory Drugs, 2023–2033

Table 43: Latin America Market Size (US$ Mn) Forecast, by Therapeutic Class – Anti-infective Drugs, 2023–2033

Table 44: Latin America Market Size (US$ Mn) Forecast, by Therapeutic Class – Anti-glaucoma Drugs, 2023–2033

Table 45: Latin America Market Size (US$ Mn) Forecast, by Product Type, 2023–2033

Table 46: Latin America Market Size (US$ Mn) Forecast, by Distribution Channel, 2023–2033

Table 47: Middle East & Africa Market Size (US$ Mn) Forecast, by Country/Sub-Region, 2023–2033

Table 48: Middle East & Africa Market Size (US$ Mn) Forecast, by Disease Indication, 2023–2033

Table 49: Middle East & Africa Market Size (US$ Mn) Forecast, by Disease Indication - Retinal Disorder, 2023–2033

Table 50: Middle East & Africa Market Size (US$ Mn) Forecast, by Therapeutic Class, 2023–2033

Table 51: Middle East & Africa Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-inflammatory Drugs, 2023–2033

Table 52: Middle East & Africa Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-infective Drugs, 2023–2033

Table 53: Middle East & Africa Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-glaucoma Drugs, 2023–2033

Table 54: Middle East & Africa Market Size (US$ Mn) Forecast, by Product Type, 2023–2033

Table 55: Middle East & Africa Market Size (US$ Mn) Forecast, by Distribution Channel, 2023–2033

List Of Figures

Figure 01: Global Market Size (US$ Mn) Forecast, 2023–2033

Figure 02: Global Company Share: Anti-glaucoma Drugs, 2018

Figure 03: Global Causes of Blindness

Figure 04: U.S. - Causes of Blindness

Figure 05: Europe - Causes of Blindness

Figure 06: Japan Causes of Blindness

Figure 07: Global Market Attractiveness, by Disease Indication, 2023–2033

Figure 08: Global Market Value Share, by Disease Indication, 2023 and 2033

Figure 09: Global Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Dry Eye, 2023–2033

Figure 10: Global Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Glaucoma, 2023–2033

Figure 11: Global Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Infection/Inflammation, 2023–2033

Figure 12: Global Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Retinal Disorders, 2023–2033

Figure 13: Global Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Uveitis, 2023–2033

Figure 14: Global Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Allergy, 2023–2033

Figure 15: Global Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Other Ophthalmic Diseases, 2023–2033

Figure 16: Global Market Attractiveness, by Therapeutic Class, 2023–2033

Figure 17: Global Market Value Share, by Therapeutic Class, 2023 and 2033

Figure 19: Global Market, by Anti-infective Drugs, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2023–2033

Figure 18: Global Market, by Anti-inflammatory Drugs Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2023–2033

Figure 20: Global Market, by Anti-glaucoma Drugs, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2023–2033

Figure 21: Global Market, by Anti-VEGF Agents, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2023–2033

Figure 22: Global Market, by Anti-allergy Drugs, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2023–2033

Figure 23: Global Market, by Others Drugs, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2023–2033

Figure 24: Global Market Value Share, by Product Type, for 2023 and 2033

Figure 25: Global Market Attractiveness, by Product Type, 2023–2033

Figure 26: Global Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Prescription Drugs, 2023–2033

Figure 27: Global Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by OTC Drugs, 2023–2033

Figure 28: Global Market Value Share, by Distribution Channel, for 2023 and 2033

Figure 29: Global Market Attractiveness, by Distribution Channel, 2023–2033

Figure 30: Global Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Online Pharmacies, 2023–2033

Figure 31: Global Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Hospital Pharmacies, 2023–2033

Figure 32: Global Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Independent Pharmacies & Drug Stores, 2023–2033

Figure 33: Global Market Value Share, by Region, for 2023 and 2033

Figure 34: Global Market Attractiveness, by Region, 2023–2033

Figure 35: North America Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2023–2033

Figure 36: North America Market Attractiveness, by Country, 2023–2033

Figure 37: North America Market Value Share, by Country, 2023 and 2033

Figure 38: North America Market Attractiveness, By Disease Indication, 2023–2033

Figure 39: North America Market Value Share, by Disease Indication, 2023 and 2033

Figure 40: North America Market Value Share, by Therapeutic Class, 2023 and 2033

Figure 41: North America Market Attractiveness, by Therapeutic Class, 2023–2033

Figure 42: North America Market Value Share Analysis, by Product Type, 2023 and 2033

Figure 43: North America Market Attractiveness, by Product Type, 2023–2033

Figure 44: North America Market Value Share, by Distribution Channels, 2023 and 2033

Figure 45: North America Market Attractiveness, by Distribution Channels, 2023–2033

Figure 46: Europe Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2023–2033

Figure 47: Europe Market Attractiveness, by Country/Sub-Region, 2023–2033

Figure 48: Europe Market Value Share, by Country/Sub-Region, 2023 and 2033

Figure 49: Europe Market Attractiveness, By Disease Indication, 2015-2025

Figure 50: Europe Market Value Share, by Disease Indication, 2023 and 2033

Figure 51: Europe Market Value Share, by Therapeutic Class, 2023 and 2033

Figure 52: Europe Market Attractiveness, by Therapeutic Class, 2023–2033

Figure 53: Europe Market Value Share Analysis, by Product Type, 2023 and 2033

Figure 54: Europe Market Attractiveness, by Product Type, 2023–2033

Figure 55: Europe Market Value Share, by Distribution Channel, 2023 and 2033

Figure 56: Europe Market Attractiveness, by Distribution Channel, 2023–2033

Figure 57: Asia Pacific Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023–2033

Figure 58: Asia Pacific Market Attractiveness, by Country/Sub-region, 2023–2033

Figure 59: Asia Pacific Market Value Share, by Country/Sub-region, for 2023 and 2033

Figure 60: Asia Pacific Market Attractiveness, by Disease Indication, 2023–2033

Figure 61: Asia Pacific Market Value Share, by Disease Indication, for 2023 and 2033

Figure 62: Asia Pacific Market Attractiveness, by Therapeutic Class, 2023–2033

Figure 63: Asia Pacific Market Value Share, by Therapeutic Class, for 2023 and 2033

Figure 64: Asia Pacific Market Value Share Analysis, by Product Type, for 2023 and 2033

Figure 65: Asia Pacific Market Attractiveness, by Product Type, 2023–2033

Figure 66: Asia Pacific Market Value Share, by Distribution Channel, for 2023 and 2033

Figure 67: Asia Pacific Market Attractiveness, by Distribution Channel, 2023–2033

Figure 68: Latin America Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2023–2033

Figure 69: Latin America Market Attractiveness, by Country/Sub-region, 2023–2033

Figure 70: Latin America Market Value Share, by Country/Sub-region, 2023 and 2033

Figure 71: Latin America Market Attractiveness, by Disease Indication, 2023–2033

Figure 72: Latin America Market Value Share, by Disease Indication, 2023 and 2033

Figure 73: Latin America Market Attractiveness, by Therapeutic Class, 2023–2033

Figure 74: Latin America Market Value Share, by Therapeutic Class, 2023 and 2033

Figure 75: Latin America Market Value Share Analysis, by Product Type, 2023 and 2033

Figure 76: Latin America Market Attractiveness, by Product Type, 2023–2033

Figure 77: Latin America Market Value Share, by Distribution Channel, 2023 and 2033

Figure 78: Latin America Market Attractiveness, by Distribution Channel, 2023–2033

Figure 79: Middle East & Africa Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2023–2033

Figure 80: Middle East & Africa Market Attractiveness, by Country/Sub-Region, 2023–2033

Figure 81: Middle East & Africa Market Value Share, by Country/Sub-Region, 2023 and 2033

Figure 82: Middle East & Africa Market Attractiveness, by Disease Indication, 2023–2033

Figure 83: Middle East & Africa Market Value Share, by Disease Indication, 2023 and 2033

Figure 84: Middle East & Africa Market Attractiveness, by Therapeutic Class, 2023–2033

Figure 85: Middle East & Africa Market Value Share, by Therapeutic Class, 2023 and 2033

Figure 86: Middle East & Africa Market Value Share Analysis, by Product Type, 2023 and 2033

Figure 87: Middle East & Africa Market Attractiveness, by Product Type, 2023–2033

Figure 88: Middle East & Africa Market Value Share, by Distribution Channel, 2023 and 2033

Figure 89: Middle East & Africa Market Attractiveness, by Distribution Channel, 2023–2033

Figure 90: Global Market Share, by Company, 2018